Evidence map›Paper›PMID 40981770›Full record

ArticleHuman molecular genetics2025

Tracing neuropathological signatures: TARDBP and C9orf72 double mutations in a Sicilian family.

Pegah Masrori, Sandra O Tomé, Lieselot Dedeene, Gauthier Remiche, Hilde Van Esch, Dietmar Rudolf Thal, Philip Van Damme

Abstract readCase Reports
In one paragraph

Article in Human molecular genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Pegah MasroriDepartment of Neurology, Neuromuscular Reference Centre, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium.ORCID 0000-0001-8247-1866
Sandra O ToméLaboratory for Neuropathology, Department of Imaging and Pathology, Leuven Brain Institute (LBI) KU Leuven, Herestraat 49, 3000 Leuven, Belgium.ORCID 0000-0001-5253-0730
Lieselot DedeeneLaboratory for Neuropathology, Department of Imaging and Pathology, Leuven Brain Institute (LBI) KU Leuven, Herestraat 49, 3000 Leuven, Belgium.
Gauthier RemicheUniversité libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), CUB Hôpital Erasme, Service de Neurologie, Centre de Référence Neuromusculaire, Route de Lennik 808, 1070 Anderlecht (Brussels), Belgium.
Hilde Van EschCenter for Human Genetics, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium.
Dietmar Rudolf ThalLaboratory for Neuropathology, Department of Imaging and Pathology, Leuven Brain Institute (LBI) KU Leuven, Herestraat 49, 3000 Leuven, Belgium.
Philip Van DammeDepartment of Neurology, Neuromuscular Reference Centre, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium.

Funding

Alzheimer's Association AARF-24-1300693BrightFocus Foundation A2022019FC1-internal funds from KU Leuven C14-17-107Een Hart voor ALS", "Laeversfonds voor ALS Onderzoek" and "the Valéry Perrier Race against ALSFWO 1225725NVlaamse Impulsfinanciering voor Netwerken voor Dementie Onderzoek IWT 135043
6 · The paper itself

Abstract

Co-occurrence of double heterozygosity in TARDBP and C9ORF72 is exceedingly rare in amyotrophic lateral sclerosis. While TARDBP mutations and C9ORF72 hexanucleotide repeat expansions have each been independently implicated in disease pathogenesis, their combined effect on disease progression and neuropathology remains unclear. We present the first study documenting a patient harboring both a TARDBP mutation and a C9ORF72 expansion, with comprehensive postmortem data available, to elucidate any additive or synergistic effects on disease course and pathological burden. Detailed clinical assessments tracked the patient's progression, and neuropathological examination was performed postmortem. The presence and extent of TDP-43 pathology and other hallmark features were evaluated and compared to known patterns in carriers of isolated C9ORF72 mutations. The patient's clinical trajectory and pathological findings did not show evidence of a more aggressive disease course or heightened pathological burden attributable to the additional TARDBP mutation. Instead, the disease manifested in a manner consistent with other C9ORF72 carriers, suggesting that double heterozygosity do not necessarily exacerbate ALS pathology.

Indexed as

Amyotrophic Lateral SclerosisC9orf72 ProteinDNA-Binding ProteinsMutationProteinsAgedDNA Repeat ExpansionFemaleHeterozygoteHumansMaleMiddle AgedPedigreeC9orf72 ProteinC9orf72 protein, humanDNA-Binding ProteinsProteinsTARDBP protein, humanALSC9ORF72NeuropathologyTAR DNA-binding protein 43

Identifiers

PMID40981770
PMCPMC12529658

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.